1. Regionala cancercentrum i samverkan. Nationellt vårdprogram Lungcancer (2024), version 8.0. Tillgänglig från: https://kunskapsbanken.cancercentrum.se/diagnoser/lungcancer/vardprogram/

1. La Fleur et al Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. Lung Cancer 2019

2. KRAS G12C Mutant Non–Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry Isaksson, Johan et al. Clinical Lung Cancer, Volume 24, Issue 6, 507 – 518

1. Regionala cancercentrum i samverkan. Nationellt vårdprogram Lungcancer (2024), verison 8.0. Tillgänglig från: https://kunskapsbanken.cancercentrum.se/diagnoser/lungcancer/vardprogram/

1. Fass. (2024, februari 29). LUMYKRAS filmdragerad tablett 120 mg [Fass-text]. Hämtad från https://www.fass.se/LIF/product?userType=0&nplId=20201221000013

2. Anne-Marie C. Dingemans et al. Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).. JCO 41, LBA9016-LBA9016(2023).

3. Barbacid M. Annu Rev Biochem. 1987;56:779-827. Ahmadzada T, et al. J Clin Med. 2018;7:153. 6. Ferrer I, et al. Lung Cancer. 2018;124:53-64. Ryan MB, et al. Nat Rev Clin Oncol. 2018;15:709-720. Cox AD, et al. Nat Rev Drug Discov. 2014;13:828-851. Neel NF, et al. Genes Cancer. 2011;2:275-287

4. Fass. (2024, februari 29). LUMYKRAS filmdragerad tablett 120 mg [Fass-text]. Hämtad från https://www.fass.se/LIF/product?userType=0&nplId=20201221000013